SARS-CoV-2 vaccine development and how Brazil is contributing

Autor(es)

Kanno, I, Alex ; Barbosa, Mayra M. F. ^[1] ; Moraes, Luana ^[1] ; Leite, Luciana C. C. ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Programa Posgrad Interunidades Biotecnol, Sao Paulo - Brazil

^[2] Kanno, Alex, I, Inst Butantan, Lab Desenvolvimento Vacinas, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: GENETICS AND MOLECULAR BIOLOGY; v. 44, n. 1, 1 2021.
• Citações Web of Science: 0

Resumo

The SARS-CoV-2 coronavirus pandemic calls for coordinated efforts by the scientific community for the development of vaccines. The most advanced strategies have focused on modifications of technologies that were already under development for other viruses, such as SARS, MERS, and even Influenza. Classic and new technologies, such as inactivated and attenuated viruses (non-replicative and replicative), DNA and mRNA vaccines, and nanoparticles containing SARS-CoV-2 antigens, are some of the strategies currently investigated. Although there is a very high expectation for the effectiveness of the most advanced vaccine candidates, there are still no established correlates of protection. Previous experience in vaccine development for other pathogens shows that differences in vaccine formulation can result in diverse immune responses and consequently, different protective properties. Therefore the importance of continuing investigations on a broad range of strategies. Expertise in vaccine development in Brazil was refocused to the new coronavirus. Impressive collaboration between institutions will support further developments until we have available a safe, effective, and economically viable vaccine. Established competence and collaborations will allow preparedness for future challenges and can also be used to address local issues as neglected infectious diseases. (AU)

• Processo FAPESP: 17/17218-0 - Implantação da plataforma de CRISPR-Cas9 em micobactéria: investigação do sistema ESX-1 na imunogenicidade de BCG
• Beneficiário: Luana Moraes
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 17/24832-6 - Desenvolvimento de vacinas baseadas em BCG recombinante: Tuberculose, Pertussis, Pneumococo e Schistosoma
• Beneficiário: Luciana Cezar de Cerqueira Leite
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 20/07547-9 - Desenvolvimento de uma vacina contra o Coronavírus SARS-CoV-2 utilizando o novo sistema apresentador de antígenos (MAPs - OMV)
• Beneficiário: Mayra Mara Ferrari Barbosa
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado